

1 **Supplemental tables**

2

3 Table 1. Phenotypic characterization of male probands and family members harboring rare  
 4 variants in *GNRHR*. \*\*\*complete loss of function; \*\*partial loss of function; \*predicted to be  
 5 pathologic; no asterisk: predicted to be benign.

Patient (and reference)	Allele 1	Allele 2	Diagnosis	Testis (ml); phallus (cm) at presentation	Testosterone levels	Number of pulses; mean LH (Q10 min sampling x 12h for LH) at presentation	Treatments	Fertility
<b>Complete Loss of GNRHR - Group 1 - cLOF/cLOF</b>								
2	C279Y***	C279Y***	nIHH					
2b	C279Y***	C279Y***	nIHH					
<b>Severe loss of GNRHR - Group 2 - cLOF/pLOF</b>								
5	R139H***	T32I**	nIHH	2 ml; micropenis		0; <1.6		
<b>Severe loss of GNRHR - Group 3 - pLOF/pLOF</b>								
10	Q106R**, S217R**	Q106R**	nIHH/Fertile eunuch	12 ml				
7	Q106R**	P96S*	Fertile eunuch	12 ml		2; 3.9	T	
8 (42)	Q106R**	Q106R**	nIHH/Reversal	17 ml; 7 cm	71 ng/dl before treatment, then 271 ng/dl	1; 3.5	hCG	Yes, after 4 months of hCG.
12	R262Q**	L166P*	nIHH/Fertile eunuch	15 ml	58 ng/dl			
12b	R262Q**	L166P*	nIHH					
<b>Moderate loss of GNRHR - Group 4 - cLOF/NL or pLOF/NL</b>								
29	A171T***	NL	KS	3 ml; micropenis			T	
10b	Q106R**, S217R**	NL	CDP					
18	Q106R**	NL	adult onset IHH	20 ml; NL	41-107 ng/dl	0; 0.64	T, GnRH, hCG	Yes (1st w/pump, 2nd w/ hCG)
16	Q106R**	NL	nIHH	9 ml		2; 3.86		
19	Q106R**	NL	KS					
17	Q106R**	NL	nIHH	1 ml				
15	Q106R**	NL	nIHH					
24b	Q106R**	NL	nIHH					
22	Q106R**	NL	nIHH					
23	Q106R**	NL	nIHH				T	
12c	L166P*	NL	CDP					
30	R262Q**	NL	nIHH	1 ml; NL	25 ng/dl	1.5; 1.9	T, GnRH, Gonadotropin	

21	R262Q**	NL	KS					
26	L117P*	NL	CDP	13 ml, 8-9 cm	363 ng/dl		No	
28	P146S*	NL	KS	1 ml (cryptorchid); 5-6 cm			T, hCG	
Normal GNRHR (not included in the four groups)								
34	F216F	NL	nIHH					
35	F216F	NL	nIHH					

6

7 Table 2. Phenotypic characterization of female probands and family members harboring rare  
 8 variants in *GNRHR*. \*\*\*complete loss of function; \*\*partial loss of function; \*predicted to be  
 9 pathologic; no asterisk: predicted to be benign.

Patient (and reference)	Allele 1	Allele 2	Diagnosis	Spontaneous breasts; menarche	Number of pulses; mean LH (Q10 min sampling x 12h for LH)	Treatment	Ovulation / conception
<b>Complete Loss of GNRHR - Group 1 - cLOF/cLOF</b>							
1	Q11fsX23***	Q11fsX23***	nIHH				No ovulation w/ either GnRH or gnts
2c	C279Y***	C279Y***	nIHH				
<b>Severe loss of GNRHR - Group 2 - cLOF/pLOF</b>							
3	M1T***, R139H***	Q106R**	nIHH	Tanner I; no menarche	0; 1.02	EP, GnRH pump	Ovulated on GnRH; conceived w/ gnts: healthy baby
4 (35)	P320L***	N10K**, Q11K**	nIHH	Tanner III; no menarche	1; 1.78	EP, GnRH, Gonadotropin	No ovulation on GnRH; twins with gnts
6	L266R***	Q106R**	nIHH	Spontaneous breasts (?); nomenarche			
<b>Severe loss of GNRHR - Group 3 - pLOF/pLOF</b>							
10c	Q106R**, S217R**	Q106R**	nIHH				
11 (41)	Q106R**	R262Q**	nIHH	No breasts; no menarche	5; 2.03	EP, GnRH, Gonadotropin	Conceived 3 times with GnRH and 2 times with gnts; miscarriages at 7-11 weeks of gestation.
11b (41)	Q106R**	R262Q**	nIHH				Conceived with gntns: healthy babies
9	Q106R**	Q106R**	KS	Tanner IV; no menarche		EP	
13	R262Q**	R262Q**	nIHH				
<b>Moderate loss of GNRHR - Group 4 - cLOF/NL or pLOF/NL</b>							
14	Q106R**	L83V	nIHH	No breasts; no menarche		EP	
14b	Q106R**	L83V	nIHH				
25	Q106R**	S168A	HA	Breasts at 11-12; menarche at 16	5; 3.9		
20	Q106R**	NL	KS				
24	Q106R**	NL	nIHH				

10d	Q106R**	NL	HA				Conceived w/o treatments
27	P146S*	NL	nIHH		5; 4.8		3 ovulations on pump, no pregnancy
32	R262Q**	NL	HA				
31	R262Q**	NL	KS				
5b	R139H*	NL	Anosmia				
21b	Q106R**	NL	cleft lip/palate				
Normal GNRHR (not included in the four groups)							
33	A50V	NL	CDP				

10

11 Table 3. Healthy family members harboring rare variants in *GN RHR*. \*\*\*complete loss of  
 12 function; \*\*partial loss of function; \*predicted to be pathologic; no asterisk: predicted to be  
 13 benign.

14

Subject	Gended	Heterozygous mutation
3c	M	M1T***, R139H***
3d	M	M1T***, R139H***
8c	M	Q106R**
8d	M	Q106R**
8e	M	Q106R**
11c	M	R262Q**
11f	M	R262Q**
11g	M	R262Q**
6c	M	Q106R**
12d	M	L166P*
3b	F	Q106R**
4b	F	N10K**, Q11K**
4c	F	P320L***
4d	F	N10K**, Q11K**
14c	F	L83V
14d	F	Q106R**
8b	F	Q106R**
24c	F	Q106R**
18b	F	Q106R**
11d	F	Q106R**
11e	F	Q106R**
6b	F	L266R***
12e	F	R262Q**
29b	F	A171T***
30b	F	R262Q**
32b	F	R262Q**

15

16

17 Table 4. SNPs used for SNP analysis of heterozygous subjects and their location within  
18 *GNRHR* gene.  
19

<b>SNP name</b>	<b>Location (relative to <i>GNRHR</i> transcriptional start site)</b>	<b>Location (relative to coordinate systems)</b>
rs2627261	1-62	68302710
rs35400155	144	68302505
rs4986942	453	68302196
rs17082306	520-75	68293178
rs13130501	549	68293074
rs13149772	550	68293073
rs17088591	741+35	68292846
rs28933074	851	68288929
rs35845954	987+583	68288888
rs35610027	987+802	68289107
rs35683646	987+809	68289114
rs17635850	987+829	68289134
rs13150734	987+1260	68288703

20

## Supplemental figure legends

Figure 1. Schematic of mutations in *GNR HR*.

Figure 2. Examples of pedigrees carrying *GN RHR* RSVs. A: family of proband #10; B: family of proband #12.








Fig. 1



-  IHH
-  Delayed Puberty (CDP)
-  Anosmia
-  Hypothalamic amenorrhea (HA)





Fig. 2